Compare NCRA & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCRA | BRTX |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | Taiwan | United States |
| Employees | N/A | 11 |
| Industry | Farming/Seeds/Milling | Managed Health Care |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.9M |
| IPO Year | 2022 | 2015 |
| Metric | NCRA | BRTX |
|---|---|---|
| Price | $0.23 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 161.0K | ★ 6.3M |
| Earning Date | 05-05-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $24.64 |
| Revenue Next Year | N/A | $287.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.19 |
| 52 Week High | $2.40 | $2.10 |
| Indicator | NCRA | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.68 | 33.95 |
| Support Level | N/A | $0.19 |
| Resistance Level | $0.48 | $0.30 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 14.00 | 52.61 |
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.